Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Episode 3: Fovista for Neovascular AMD: Exciting Results from a Phase II Trial

In the third episode of Retina Today Journal Club moderator Jonathan Prenner, MD, turns the camera on Richard Kaiser, MD. The two discuss the phase II clinical trial results of anti-platelet derived growth factor (PDGF) combination agent Fovista (formerly E10030, Ophthotech Corporation).

The drug demonstrated efficacy of a unique biologic approach to treating AMD when used in combination with ranibizumab (Lucentis, Genentech) for the treatment of wet AMD. Based on data presented, Dr. Kaiser explains the theory and implementation of this combination strategy for AMD.

58 / 60 Series: Retina Today Journal Club

More Videos in this Series